Astria Therapeutics Inc (NASDAQ:ATXS) Reports Narrower-Than-Expected Q2 2025 Loss and Strong Cash Runway

ASTRIA THERAPEUTICS REPORTS Q2 2025 RESULTS: NARROWER-THAN-EXPECTED LOSS, CASH RUNWAY EXTENDED

Astria Therapeutics (NASDAQ:ATXS [https://www.chartmill.com/stock/quote/ATXS]) reported a net loss of $0.57 per share for the second quarter of 2025, slightly better than the consensus analyst estimate of a $0.60 loss. Revenue remained at $0.0, in line with expectations, as the company continues to focus on clinical-stage development rather than commercial sales.

FINANCIAL PERFORMANCE VS. ESTIMATES

* EPS: Reported at -$0.57, beating estimates of -$0.60.
* REVENUE: $0.0, matching expectations.
* CASH POSITION: The company ended the quarter with $259.2 MILLION in cash and short-term investments, down from $328.1 million at the end of 2024. Management expects current funds, including a recent $16 million upfront payment from Kaken Pharmaceutical, to support operations into 2028.

The narrower loss was driven by disciplined spending, though R&D expenses rose to $25.9 MILLION (up from $20.7 million in Q2 2024) due to increased clinical trial activity. General and administrative costs also climbed to $9.9 MILLION, reflecting company growth.

MARKET REACTION

Following the earnings release, Astria’s stock showed MINIMAL IMMEDIATE AFTER-HOURS MOVEMENT, suggesting investors had largely priced in the results. Over the past month, shares have gained 5.4%, possibly reflecting optimism around clinical progress rather than short-term financials.

KEY PIPELINE UPDATES

*
NAVENIBART (STAR-0215) – The lead candidate for hereditary angioedema (HAE) continues to advance:

* PHASE 3 ALPHA-ORBIT TRIAL ENROLLMENT IS ONGOING, with top-line data expected in early 2027.
* POSITIVE LONG-TERM DATA from the ALPHA-SOLAR trial showed a 92% MEAN REDUCTION IN MONTHLY ATTACK RATES, reinforcing its best-in-class potential.
* STRATEGIC PARTNERSHIP WITH KAKEN PHARMACEUTICAL for Japanese commercialization, bringing $16 million upfront and potential milestone payments.

*
STAR-0310 (OX40 ANTAGONIST FOR ATOPIC DERMATITIS) – Phase 1a trial in healthy subjects is underway, with early proof-of-concept data expected in Q3 2025.

OUTLOOK VS. ANALYST ESTIMATES

While Astria did not provide formal financial guidance, analysts project:

* Q3 2025 EPS ESTIMATE: -$0.61
* FULL-YEAR 2025 EPS ESTIMATE: -$2.25
The company’s extended cash runway suggests it can fund operations without near-term dilution, a positive for long-term investors.

CONCLUSION

Astria’s Q2 results reflect steady progress in its clinical programs, with a slightly better-than-expected loss and a solid cash position. The lack of a dramatic market reaction indicates that investors are focused on long-term catalysts, particularly the Phase 3 data for navenibart in 2027.

For more detailed earnings estimates and future projections, see Astria Therapeutics’ earnings estimates page [https://www.chartmill.com/stock/quote/ATXS/earnings-estimates].

DISCLAIMER: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.